| Sep 14 |
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
|
| Sep 13 |
Summit boosts Instil, BioNTech as lead drug beats Merck’s Keytruda
|
| Sep 13 |
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
|
| Sep 10 |
Private equity firms are Instil Bio, Inc.'s (NASDAQ:TIL) biggest owners and were rewarded after market cap rose by US$52m last week
|
| Aug 14 |
Instil Bio GAAP EPS of -$2.29
|
| Aug 13 |
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 1 |
Instil Bio to in-license cancer candidates from ImmuneOnco
|
| Aug 1 |
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
|
